Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426865 | 0.93 | MAPT (0.55) | DRD2L3MBTL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL15784402 | 0.91 | DRD4 (0.57) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL8134006 | 0.85 | DRD2 (0.58) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL7754766 | 0.84 | DRD2 (0.55) | DRD2L3MBTL1DRD4MAPTNPC1 | |
| SCHEMBL21712168 | 0.84 | DRD2 (0.64) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL30912017 | 0.84 | DRD2 (0.64) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL21712173 | 0.84 | DRD2 (0.57) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL981641 | 0.82 | NOTUM (0.60) | DRD2MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL27872558 | 0.82 | DRD2 (0.57) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 | |
| SCHEMBL6966940 | 0.82 | DRD2 (0.61) | DRD2L3MBTL1DRD4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2021-08-05 | — | — | US | disclosed |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2021-08-05 | — | — | US | disclosed |
| US-11014892-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014892-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2020-02-20 | — | — | US | disclosed |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2020-02-20 | — | — | US | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | DRD2 338/4885L3MBTL1 2834/4885DRD4 739/4885 |
| US-11014892-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | DRD2 338/4885L3MBTL1 2834/4885DRD4 739/4885 |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | HTR1F, HTR1A, TFAM | DRD2 338/4885L3MBTL1 2834/4885DRD4 739/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | DRD2 3618/4885L3MBTL1 4249/4885DRD4 4405/4885 |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | HTR1F, HTR1A, TFAM | DRD2 338/4885L3MBTL1 2834/4885DRD4 739/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | DRD2 3487/4885L3MBTL1 2633/4885DRD4 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.